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Abstract
Introduction
Dalbavancin is an antibiotic within the class of medications known as lipoglycopeptides.
This medication is given to patients presenting to the hospital with acute skin and skinstructure infections (ABSSSI). This is a unique medication because it is given as a one-time
dose in the outpatient setting and it could prevent patients from requiring admission to
the hospital.
Methods
The emergency department (ED) at Good Samaritan community hospital performed a trial
period with dalbavancin and data was collected from November 2018 to March 2020.
Retrospective chart review was performed to obtain patient data and outcomes. Patients
would be contacted by a clinical pharmacist within 72 hours of treatment.
Results
Ten patients received dalbavancin in the ED during the trial period. Two patients were
reached on follow-up and noted improvement in the initial lesion. Two patients returned
to the ED within 30 days, and one of these patients was admitted.
Discussion
Dalbavancin provides another therapy option to the treatment of ABSSSIs. The one-time
dosing is advantageous for outpatient treatment of patients presenting with ABSSSIs. This
case series suggests dalbavancin can have positive effects when implemented in
community hospital settings.
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Introduction
Acute bacterial skin and skin-structure infections (ABSSSI) is a common reason
that patients present to emergency departments (ED) (1). The causative pathogen in
patients presenting with ABSSSI is typically gram-positive organisms, particularly
Staphylococcus aureus (2). Patients have several options for treatment. These options
include inpatient or outpatient treatment in combination with intravenous (IV) or oral
antibiotics.
With such a range of treatment options it becomes difficult to determine what
treatment is best for patients presenting with ABSSSIs. Inpatient treatment is typically
reserved for more severe cases of ABSSSIs that may need additional supportive care, and
outpatient treatment provides a convenient option for patients that present with milder
cases of ABSSSIs. Patients treated in the outpatient setting have successful outcomes and
avoid the inconvenience of being admitted to the hospital (3). Outpatient treatment
typically consists of oral antibiotics for ABSSSIs. Newer antibiotics have been developed
that allow patients to receive treatment in the outpatient setting in order to avoid
admission to the hospital for the sole purpose of receiving IV antibiotics. This class of
antibiotics is known as lipoglycopeptides and includes dalbavancin (4). Dalbavancin’s
single IV infusion regimen is Food and Drug Administration (FDA) approved for the
indication of ABSSSI that are caused by susceptible organisms (5). Due to the convenience
of one-time dosing, patients can avoid hospital admission and receive adequate coverage
for the majority of ABSSSI cases.
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Dalbavancin has positive public health implications. Namely, it provides another
option to the armamentarium of medications used for ABSSSI. Use of dalbavancin also
provides convenience for patients and providers through its one-time administration.
Dalbavancin also allows patients to receive adequate outpatient treatment and thus
avoid a hospitalization for the treatment of ABSSSI.
Dalbavancin is currently used at the ED associated with the University of
Kentucky’s (UK) academic medical center. UK’s academic medical center has many
resources such as ED pharmacists and attending physicians, as well as infectious disease
pharmacists and physicians. Access to these resources and personnel allow for proper
administration, documentation and follow-up for dalbavancin through a collaborative
institutional protocol. The community hospital associated with UK, known as Good
Samaritan, does not have a dedicated ED pharmacist at this time. A trial period of
dalbavancin utilization was initiated at Good Samaritan’s ED. The trial period was initiated
in November of 2018 and included 10 patients.
This retrospective case series was performed for patients that received
dalbavancin within the ED at Good Samaritan Hospital. This case series aims to describe
the results of patients receiving dalbavancin at Good Samaritan, as well as identify areas
of process improvement for the administration of dalbavancin within a smaller
community ED setting.

7

Literature Review
Presentation of ABSSSI
ABSSSI is a common condition that is seen by practitioners within emergency
departments. The FDA defines ABSSSI as cellulitis/erysipelas, wound infection, and major
cutaneous abscess, with a surface area of the lesion greater than or equal to 75m2. In
addition, there are two categories of ABSSSI: purulent, which includes cellulitis and
erysipelas, and nonpurulent, which includes abscesses (6). The variation could range from
those presenting with minor cases of uncomplicated cellulitis to those presenting with a
major cutaneous abscess, along with systemic symptoms (7). While these patients can
have a multitude of presentations, initial treatment will typically be directed towards
gram-positive cocci (4). Others present with gram-negative pathogens, anaerobes or a
mixture. These patients can typically be identified through specific risk factors and
comorbidities that are listed in table 1 (8).
Table 1. Gram Negative Organism Risk Factors
Risk Factors for Gram-Negative or
Co-morbidities associated with gramanaerobic infections
negative or anaerobic infections
Surgical site infections
Diabetes mellitus
Axillary cavity
Cirrhosis
Gastrointestinal tract
Intravenous drug abuse
Perineum
Subcutaneous drug abuse
Female genital tract

Patients that present to the ED with ABSSSI can be treated in the outpatient
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setting and the Infectious Diseases Society of America (IDSA) recommends this route of
treatment, when possible (9). However, there are patients that present to the ED that
will ultimately need to be hospitalized. Determination of proper route of treatment is
subjective and can vary between providers. One study found that patients were most
likely to be hospitalized when they needed IV antibiotics, had a history of fever, presented
with a larger lesion, had any co-morbidity and were age >65 years. However, the study
also found that nearly all the patients were admitted to non-critical areas and few had
serious complications.

This finding raises the possibility that patients could have

experienced successful outcomes with outpatient treatment (10). It must also be
considered that patients treated within the inpatient setting are exposed to risks such as
adverse drug reactions and infection (11).
Treatment of ABSSSI
Patients that present to the ED with ABSSSI have a multitude of treatment options.
These treatments are typically aimed at gram-positive organisms such as Staphylococcus
aureus and Streptococcus spp. (12). The 2019 review to the IDSA ABSSSI guidelines notes
that methicillin-resistant Staphylococcus aureus (MRSA) needs to be considered when
treating patients who present with ABSSSI (4). This consideration is paramount within
areas that have higher rates of MRSA demonstrated by antibiogram patterns. There are
many drugs that have good activity against MRSA, but it becomes difficult to determine
which choice is the best for patients presenting to the ED with ABSSSI.
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Table 2. Antibiotics Available for ABSSSI Treatment
Drug
Vancomycin
Linezolid
Tedizolid
Clindamycin

Daptomycin
Ceftaroline
Doxycycline
Trimethoprim-sulfamethoxazole
Delafloxacin
Omadacycline
Dalbavancin
Oritavancin

Considerations in therapy
Drug of choice for MRSA; requires drug
monitoring; nephrotoxic effects; IV only
Bacteriostatic; hematologic effects; oral
or IV
Bacteriostatic; hematologic effects; oral
or IV
Bacteriostatic; inducible resistance with
MRSA; risk of Clostridioides difficile;
oral or IV
Bactericidal; potential for myopathies; IV
only
Bactericidal; IV only
Bacteriostatic; oral or IV
Bactericidal; oral or IV
Tendon rupture; CNS effects; oral or IV
Oral or IV
Bactericidal; IV only; single infusion
Bactericidal; IV only; single infusion

As noted in table 2, there are many options for treatment of patients presenting
with ABSSSI. Vancomycin is the drug that is commonly started as the initial treatment for
patients presenting with more severe ABSSSIs. Vancomycin is chosen due to its superb
coverage of gram-positive organisms, as well as its effectiveness against MRSA (13).
However, vancomycin is an IV drug that is typically given twice daily, and patients will
often be admitted to the hospital in order to receive the proper dosing.
Drawbacks to the use of vancomycin include risk of kidney injury with high trough
concentrations (>20mg/L), higher daily doses (>4g per day), longer duration of therapy
(>7 days) and concomitant dosing with other antimicrobials such as piperacillin10

tazobactam (14, 15). Due to the risk of nephrotoxicity, vancomycin requires therapeutic
drug monitoring and dosage adjustments that can be time and labor intensive (16).
Conversely, patients that present to the ED with ABSSSI and mild to no systemic
symptoms can be candidates for outpatient treatment. Outpatient is preferred, when
possible, due to cost savings and the avoidance of unintended consequences associated
with hospital admissions (3, 11). Traditionally, patients that receive outpatient treatment
will receive oral medications due to the convenience from a patient’s perspective. As
noted in table 2, there are several medications that have oral options, which include
linezolid, doxycycline and trimethoprim-sulfamethoxazole. These all have coverage
against MRSA and can be effective options when a patient is deemed to be a candidate
for outpatient therapy. In addition, patients that are admitted to the hospital to receive
IV antibiotics may be discharged within a few days after showing signs of improvement
and then can be switched to oral antibiotics to finish a 7 to 10-day treatment course (4).
Patients can receive IV antibiotics within the outpatient setting and this is known
as outpatient parenteral antibiotic therapy (OPAT).

The IV medications will be

administered through a temporary IV line that is placed. This method allows patients to
receive proper antibiotic therapy within their own home, an infusion center or a longterm medical facility. This method is a convenient option for patients that have help from
caregivers or in-home medical staff (home health nurses, etc.). However, not every
patient is a candidate to receive OPAT. There needs to a competent and adherent patient
or caregiver within the home of a patient receiving OPAT. This adult also must be able to
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learn and perform sterile infusion, as well as communicate with a medical team (17). Any
of the IV drugs listed in table 2 can be utilized for patients within the outpatient setting.
There are several downsides to utilizing OPAT. As mentioned, this option requires
patients to have an IV access line placed and this can lead to adverse events. This IV
access line can become infected without proper sanitizing techniques, or a clot can
develop, which prevents drug from being properly administered through the line. In
addition to this, several antibiotics need therapeutic drug monitoring due to risk of
incorrect drug concentration levels and this requires weekly check-ups with a healthcare
provider (17).
Dalbavancin is a new IV medication that can be used within the outpatient setting.
It is unique in the fact that it is a single IV dose which is FDA-approved for the treatment
of ABSSSIs. The convenience of a one-time dose is very appealing to patients, and it
avoids therapeutic drug monitoring or the need for an IV access line to be placed. Also,
proper dalbavancin utilization could lead to cost savings through avoidance of inpatient
hospital days (18). Dalbavancin has a favorable side effect profile with mild adverse
reactions being identified. The major adverse events include nausea, headache and
diarrhea. Also, dalbavancin has little effect on cytochrome P450 substrates and therefore
there are few clinically relevant drug interactions (5).
Outpatient dalbavancin versus inpatient treatment
The FDA’s approval of dalbavancin for the treatment of ABSSSI raises the question
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of dalbavancin’s place in therapy. Studies note that one role in therapy could be for
patients that are being admitted to the hospital for the sole purpose of receiving IV
antibiotics. Talan et al found that 41.5% of patients presenting with ABSSSI were
admitted to the hospital for the sole purpose of receiving IV antibiotics and none of these
patients required intensive critical unit (ICU) transfer (10). This finding demonstrates that
many patients could utilize outpatient therapy due to the lack of high-level care needed.
To add to this, data from 2008 to 2010 showed that patients presenting with ABSSSIs that
were subsequently hospitalized, had a mortality of 0.5%. This statistic demonstrates that
many ABSSSI patients have no need to be hospitalized (19). Assuming these patients have
no contraindications to dalbavancin, this could be the area where dalbavancin could be
utilized for cost-savings and patient convenience.
Another study compared the use of vancomycin followed by oral linezolid to the
use of dalbavancin weekly for the treatment of patients with ABSSSIs. Specifically, these
were patients with one or more systemic signs of infection who were thought to need at
least three days of IV therapy (20). Previously dalbavancin had been approved for a
regimen of 1 gram on day 1 followed by 500mg on day 8, but it was later proved that a
single 1500mg infusion was noninferior (21). The study found that dalbavancin was not
inferior to the conventional regimen of IV plus oral antibiotics. In addition to this, patients
receiving dalbavancin had fewer side effects as compared to those that received
vancomycin-linezolid combination (20).
There is good evidence for using dalbavancin for patients that would typically be
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admitted to the hospital for the sole purpose of receiving IV antibiotics. However, it
becomes important to understand when patients are not candidates for dalbavancin and
should be admitted to the hospital. Currently there is not a definitive algorithm for when
patients should be hospitalized due to an ABSSSI. IDSA guidelines note that patients that
should likely be admitted to the hospital include those with signs of sepsis, suspicion of
deep tissue infections (i.e. necrotizing fasciitis), or exacerbation of comorbidities (4).
These patients are best managed within the inpatient setting due to medical concerns
that go beyond a skin infection.

Also, if a patient presents with symptoms or

comorbidities listed in table 1, they will need additional coverage that typically warrants
admission to the hospital.
Use of dalbavancin at the University of Kentucky Medical Center
Currently, dalbavancin is utilized within the University of Kentucky emergency
department and has shown favorable outcomes. In 2016, a case series was performed in
order to assess the feasibility of using dalbavancin (22). The antimicrobial stewardship
team at UK developed guidelines to allow for proper selection of patients who could
receive dalbavancin. As the literature shows, the guideline first determined whether the
patient would be admitted to the hospital for IV antibiotics to treat ABSSSI. If the patient
is 18 years of age or older and has a lesion 75 cm2 or greater, then they become a
candidate for dalbavancin. However, there are several contraindications to the use of
dalbavancin, which are listed in table 3 (23).
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Table 3. Contraindications to Dalbavancin

-

Contraindications to dalbavancin
Diabetic foot infection/compromised vascularity
Necrotizing fasciitis/gangrene
Altered mental status
Prior antibiotic failure and requires inpatient support
Bacteremia, endocarditis, osteomyelitis, catheter infection
Unstable comorbidities (ex: diabetic ketoacidosis, acute exacerbation)
Immunocompromised (ex: CD4 < 200 cells/mm3 , neutrophils < 500 cells/mm3
, uncontrolled diabetes)
Burn
Severe sepsis/shock
Severe vancomycin allergy
Severe hepatic disease
Surgical site infection
Pregnancy

Following up with patients that receive dalbavancin is an important part of the
treatment algorithm. The protocol developed at UK has the emergency department
pharmacist follow-up with patients within the next 72 hours to monitor improvement.
This is the time period when most patients experience clinical improvement and is an
endpoint that has been used for outcomes in previous studies (24). After the follow-up
interaction, patient’s clinical outcomes are recorded within REDCap™ (22).
The University of Kentucky has a community hospital that is affiliated with their
healthcare system, Good Samaritan Hospital. This community hospital is a smaller
institution that is equipped with an ED. However, Good Samaritan’s ED does not have an
emergency department pharmacist on site, who is typically responsible for screening,
documentation and follow-up, as it relates to dalbavancin. Thus, dalbavancin is utilized
15

less frequently at Good Samaritan’s ED and it remains to be seen if dalbavancin will be
effective within this community hospital.
Purpose
This case series was performed to describe the results of utilizing dalbavancin
within the community hospital setting at Good Samaritan’s ED. The primary goal of this
case series was to assess patient outcomes for those that received dalbavancin within
Good Samaritan’s ED from November 2018 to March 2020. The secondary goal was to
determine process improvement areas, including follow-up and documentation
opportunities.
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Methods
All data were extracted from electronic medical records (EMR) of patients that
presented to the ED at Good Samaritan Hospital. Approval was obtained from the
University of Kentucky Institutional Review Board (IRB) to extract and analyze
retrospective health record data for patients that received dalbavancin within the ED at
Good Samaritan Hospital. The approved time period for data collection begins in
November, 2018, and ends October 26, 2020. The inclusion criteria for the case series
were patients ≥18 years of age with an ABSSSI ≥ 75 cm2 that had received dalbavancin at
Good Samaritan’s ED from November 2018 to March 2020. The business partner director
for pharmacy services at UK was able to obtain the correct patient records based on billing
for dalbavancin. Patients were also identified by performing a keyword search in the
admission History and Physical (H&P).
Through retrospective chart review, the patient characteristics were determined.
Patients’ age and gender were pulled directly from the patient profile. The ED admission
note was reviewed for the determination of each patient’s diagnosis, comorbid conditions
and any past medical history related to ABSSSIs, as well as any hospital visits after the
administration of dalbavancin.
Because dalbavancin administration was a new process, physicians needed to
ensure patients were appropriate candidates for dalbavancin therapy. Table 4 (23)
identifies those who would need to be contacted for approval of dalbavancin
administration. There was documentation within each patient’s profile to describe the
17

appropriateness of dalbavancin. All other information related to the screening process,
additional therapy, administration of dalbavancin and the patient follow-up were located
in this documentation. The dalbavancin screening determination process is presented in
figure 1 (23).
Table 4. Provider Approval for Dalbavancin Administration
Day
Weekdays

Time
0600 - 1800

1800 - 0600
Weekends

0600 - 1800
1800 - 0600

Provider Approval Needed
ED Attending Physician
GS Clinical Pharmacist On Call
ID Pharmacist or Physician
ED Attending Physician
GS Operations Pharmacist
ED Attending Physician
GS Clinical Pharmacist On Call
ED Attending Physician
GS Operations Pharmacist
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Figure 1. Dalbavancin Approval Algorithm
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Results
From November 2018 to March 2020, patients that received dalbavancin were
identified. At the end of the trial period, ten patients had received dalbavancin. The
average age of patients receiving dalbavancin was 42.7 years, with a range of 23 to 68.
Seven of the patients were female and three male.
During the trial period, the patients’ lesions were identified and described. Five
(50%) of the patients presenting to the ED had an ABSSSI occurring on their lower
extremities.

Four (40%) patients presented with ABSSSI occurring on their upper

extremities and 1 (10%) presented with ABSSSI on their abdomen.
Most patients during this trial period had documented comorbidities. The most
common comorbidity observed in this case series was IV drug use (40%).

Other

documented comorbidities included hypertension (HTN) (20%), hyperlipidemia (HLD)
(20%) and morbid obesity (20%). Wound culture data was obtained for 2 (20%) patients.
Dalbavancin properly covered the MRSA found in one patient and the MSSA in the other.
The patient with MSSA also had growth of Escherichia coli and Enterobacter cloacae, this
patient received an additional antibiotic due to the gram-negative organisms.
Two patients were contacted for follow-up within 72 hours, one of which received
an incision and drainage of abscess the next day. A third patient returned to the ED within
72 hours, and a fourth patient returned 16 days later to be admitted due to a gramnegative organism, Pseudomonas fluorescens, in the bloodstream. The two patients

20

contacted noted improvement in their initial lesion. The third patient that returned to
the ED within 72 hours presented with new skin lesions. This patient noted improvement
in their initial lesion, but due to an underlying condition this patient presented with new
skin lesions. The patient that was admitted 16 days later for Pseudomonas fluorescens in
their bloodstream also had a positive wound culture showing MRSA. This patient received
oral levofloxacin for their bacteremia.
Adverse effects were minimal, as they were only noted in two (20%) patients. One
patient experienced nausea during their infusion of dalbavancin. The other patient
experienced dizziness during their infusion of dalbavancin.
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Table 5. Results of Dalbavancin administration
Gender

Age

ED Diagnosis

Comments/Notes

Comorbid
Conditions

F

I&D

Outcome

59

Cellulitis of right
lower extremity

HTN, morbid
obesity,
T2DM, HLD

N/A

Follow-up phone call
from ED pharmacist patient reported
improvement

F

68

Cellulitis of right
upper extremity

Breast cancer

N/A

No follow-up
information

M

38

Cellulitis of right
upper extremity

IVDU

N/A

F

37

Cellulitis of
bilateral lower
extremities

Previous use of
antibiotics for cellulitis
with Bactrim and
Keflex, no cultures
taken, WBC of 6.94,
dizziness experienced
during infusion
Had previous episodes
of cellulitis and had
taken clindamycin,
negative BC, WBC of
14
Frequent hospital visits
due to IV drug abuse,
negative BC, WBC of
6.8
Negative BC, WBC of
13.8

IVDU

N/A

No follow-up
information, subsequent
hospitalizations due to
IVDU
No follow-up
information

F

28

Stomach abscess

Hidradenitis
suppurativa,
morbid
obesity,
asthma

N/A

Patient returned to ED
with new abscess but
noted improvement on
the initial abscess

F

28

Abscess of right
arm

Patient was on chronic
doxycycline and had
recently been taking
clindamycin as well for
abscesses, negative BC,
WBC of 14, nausea
experienced during
infusion
History of failed oral
antibiotics, signs of
UTI, positive BC for
Pseudomonas
fluorescens, WBC of
7.3

IVDU,
endometriosis,
HPV

Yes - MRSA

No follow-up, patient
presented 16 days later
with fever – prescribed
levofloxacin due to
initial positive BC

F

44

Cellulitis of
bilateral upper
extremities

IVDU,
hepatitis C

N/A

No follow-up
information

F

45

Cellulitis of
bilateral thighs
and buttocks

Chronic back
pain

N/A

No follow-up
information

M

57

Cellulitis/abscess
of right lower
extremity

Chief complaint was
stomach pain, cellulitis
was related to injection
sites, no BC, WBC of
14.6
Received concomitant
antibiotics for STD
prophylaxis and UTI,
negative BC, WBC of
7.2
Presented to ED next
day due to positive BC
for Staphylococcus
aureus, received
abscess I&D, WBC of
16.2

HTN, HLD

Yes- MSSA,
E. coli,
Enterobacter
cloacae

Follow-up phone call
from ED pharmacist –
patient reported
improvement – patient
followed up with PCP
for other bacteria and
received ciprofloxacin

M

23

Bilateral lower
extremity
cellulitis

Previously hospitalized
for cellulitis and
received vancomycin
with oral transition to
Bactrim, negative BC,
WBC of 13.4

None

N/A

No follow-up
information
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Limitations
There are several limitations to this study. This was a retrospective case series
with a small sample of 10 patients. All data was extracted from an EMR. In addition, this
case series was performed at a single hospital’s ED, limiting our ability to draw
conclusions. Follow-up information was missing for the majority of patients in this case
series.

Long-term effects of dalbavancin cannot be properly tracked if follow-up

information is not obtained from patients.

Discussion
The case series performed at Good Samaritan’s ED showed improvement of
symptoms and minimal side effects for those that received dalbavancin for patients who
were able to be contacted. This finding suggests that dalbavancin, when implemented
properly, may be a viable option for patients presenting to a community ED with an
ABSSSI. For the two patients that were contacted within 72 hours, both patients noted
improvement of the initial lesion. A third patient returned to the ED for new skin lesions
but noted the initial lesion had improved. This patient-reported improvement suggests
positive outcomes for those that received dalbavancin and were available for follow-up.
This finding aligns with previous studies that show positive outcomes for those receiving
dalbavancin for ABSSSIs (20, 25).
Patients with documented follow-up showed improvement but this case series
23

demonstrates the problem of loss to follow-up. The majority (60%) of patients had no
documented follow-up from either the pharmacist or subsequent hospital visits. This is
problematic for several reasons. Drug effects cannot be monitored when outcomes are
unavailable. It becomes difficult to properly monitor effects of a drug when outcomes
cannot be tracked. However, this case study is not alone in experiencing difficulties with
patient follow-up.

A previous study analyzing the implementation of dalbavancin

demonstrated difficulties in following up with patients after they have left the hospital
(26).
IV drug abuse was a common comorbidity among patients within this case series.
Previous studies have shown that those who inject IV drugs have a greater risk for
infectious diseases, including bacterial skin infections (27, 28). The single IVDU in the case
series who had culture results showed MRSA as the offending agent. Not only is
dalbavancin effective for more difficult pathogens such as MRSA, but it also provides a
convenient treatment regimen that can improve compliance.

Other outpatient

treatments require oral or IV administration over several days, which introduces the risk
of patient non-compliance.

Dalbavancin is monitored for the one-time dose and

eliminates any risk of non-compliance, which is a concern within the IVDU population
(29). When a full dose of antibiotics is taken appropriately there is a better chance of
successful treatment and a lower chance of antibiotic resistance.
Non-compliance is not a problem that is specific to IVDU. Previous studies have
shown that the population in general has poor adherence rates, with nearly 15% stopping
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their antibiotics early (30). Noncompliance puts patients at risk of treatment failure in
the short term. In the long term, non-compliance contributes to the public health issue
of antibiotic resistance. This problem may not present as quickly as treatment failure, but
antibiotic resistance still has far-reaching effects. Infections with antibiotic resistant
organisms are harder to treat and can have worse outcomes. The CDC estimates that
nearly 3 million people annually in the U.S. are infected with an antibiotic resistant
bacteria or fungi. In addition, the CDC estimates that nearly 35,000 people will die of
these difficult-to-treat infections (31). Completing antibiotic courses is a simple yet
effective method to combat antibiotic resistance. The one-time dosing of dalbavancin
offers an effective solution when providers are concerned about a patient’s adherence.
Adverse effects appear to have been minimal in this case series with only two
patients experiencing problems associated with dalbavancin administration, although the
majority of patients were lost to follow-up. One patient experienced nausea as the
infusion was being given. The other patient experienced dizziness that was associated
with the infusion.

Both reactions align with adverse effects reported in previous

dalbavancin studies. The phase III trials that proved the non-inferiority of dalbavancin to
comparators showed a favorable side effect profile. These studies noted common side
effects to be nausea, diarrhea, and pruritus (20). These are mild side effects when
compared to the side effects of similar drugs such as vancomycin and linezolid.
Vancomycin can be associated with more severe side effects such as acute kidney injury
(14). In addition, a serious side effect associated with linezolid is hematologic changes
such as thrombocytopenia and anemia (32). If patients were to have a kidney deficiencies
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or previous hematologic abnormalities, dalbavancin could be a reasonable alternative as
opposed to vancomycin or linezolid.
A potential benefit of dalbavancin is the cost effectiveness. A cost analysis was
not performed in this case series, but previous literature shows potential cost-savings
from the use of dalbavancin. This is because dalbavancin is traditionally used for patients
that would be admitted to the hospital. Instead of incurring the high cost of a hospital
stay, patients receive their dalbavancin infusion in the ED and then are discharged. A
retrospective study at UK’s academic medical center compared the cost of dalbavancin to
a group of patients that were admitted to the hospital for ABSSSIs. The patients that
received dalbavancin had a direct cost avoidance of $4,560 (33), demonstrating
substantial cost-savings when dalbavancin is properly utilized.
Implications
Dalbavancin is a drug that has several benefits when treating ABSSSI. Dalbavancin
plays a unique role because it is an outpatient treatment that can be used for patients
who would have previously been admitted to the hospital for IV antibiotics. On a larger
scale, this case series adds to the growing body of literature that illustrates the potential
effectiveness of dalbavancin.
This case series has public health implications regarding antibiotic resistance.
More frequent use of dalbavancin has the potential reduce patients’ prescription
antibiotic nonadherence in patients and thus reduce antibiotic resistance. Healthcare
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providers can confirm that patients receive a full antibiotic regimen with the
administration of dalbavancin thus ensuring that patients are adequately treated, while
mitigating the chance of antibiotic resistance.
At the institutional level, this case series adds to the literature by addressing the
outcomes of implementing dalbavancin within a community ED. Community EDs do not
have the resources of larger academic medical centers, and this could make it more
difficult to justify implementing a new antibacterial such as dalbavancin. This case series
provides one example of the processes that could be implemented to begin using
dalbavancin. Also, this case series provides insight into the problems that can be
encountered when implementing dalbavancin within a community ED.
This case series also demonstrates the infrequent use of dalbavancin. This case
series extended over sixteen months but there were only ten patients that received
dalbavancin. Providers’ comfort with prescribing dalbavancin appears to be an obstacle.
Providers know what to expect when prescribing a drug such as vancomycin for ABSSSIs.
Dalbavancin, however, is a new drug that has an unconventional dosing regimen. This
situation presents an opportunity for pharmacists to educate providers on dalbavancin’s
place in therapy. In addition, pharmacy staff can work with providers to ensure proper
protocols for dalbavancin administration. With these measures in place, cost savings and
convenient dosing of dalbavancin can be fully realized (34).
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